ФАКТОРЫ ПРОГНОЗА ПОЛОЖИТЕЛЬНЫХ РЕЗУЛЬТАТОВ МУЛЬТИФОКАЛЬНОЙ БИОПСИИ ЗОНЫ ВЕЗИКОУРЕТРАЛЬНОГО АНАСТОМОЗА У БОЛЬНЫХ С БИОХИМИЧЕСКИМ РЕЦИДИВОМ ПОСЛЕ РАДИКАЛЬНОЙ ПРОСТАТЭКТОМИИ ПО ПОВОДУ РАКА ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ
https://doi.org/10.17650/1726-9776-2011-7-4-59-66
Аннотация
Об авторах
П. Д. Демешко
ГУ Научно-практический центр онкологии и медицинской радиологии им. Н.Н. Александрова, Минск, Республика Беларусь
Беларусь
Беларусь
А. В. Карман
ГУ Научно-практический центр онкологии и медицинской радиологии им. Н.Н. Александрова, Минск, Республика Беларусь
Беларусь
Беларусь
О. Г. Суконко
ГУ Научно-практический центр онкологии и медицинской радиологии им. Н.Н. Александрова, Минск, Республика Беларусь
Беларусь
Беларусь
С. А. Красный
ГУ Научно-практический центр онкологии и медицинской радиологии им. Н.Н. Александрова, Минск, Республика Беларусь
Беларусь
Беларусь
Список литературы
1. Heidenreich A., Aus G., Bolla M. et al. EAU guidelines of prostate cancer. Eur Urol 2008;53:68–80.
2. Laufer M., Pound C.R., Carducci M.A. et al. Management of patients with rising prostate-specific antigen after radical prostatectomy. Urology 2000; 55: 309–15.
3. Partin A.W., Oesterling J.E. The clinical usefulness of prostate specific antigen: update 1994. J Urol 1994;152:1358–68.
4. Han M., Partin A.W., Zahurak M.et al. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 2003; 169:517–23.
5. Алгоритмы диагностики и лечения злокачественных новообразований. Под ред. И.В. Залуцкого, Э.А. Жаврида. Минск, 2007; с. 351−72.
6. Zincke H., Osterling J.E., Blute M.L. et al. Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol 1994; 152:1850–7.
7. Leventis A.K., Shariat S.F., Slawin K.M. Local recurrence after radical prostatectomy. Correlation of US features with prostatic fossa biopsy findings. Radiology 2001; 219: 432–9.
8. Scattoni V., Roscigno M., Raber M. et al. Biopsy of the vesico-urethral anastomosis after radical prostatectomy: when and how. Eur Urol 2002;38 (Suppl 1):89–95.
9. Goldenberg S.L., Carter M., Dashefsky S., Cooperberg P.L. Sonographic characteristics of the urethrovesical anastomosis in the early post-radical prostatectomy patient. J Urol 1992;147:1307–9.
10. Parra R.O, Wolf R.M., Huben R.P. The use of transrectal ultrasound in the detection and evaluation of local pelvic recurrences after a radical urological pelvic operation. J Urol 1990;144:707–9.
11. Lightner D.J., Lange P.H., Reddy P.K., Moore L. Prostate specific antigen and local recurrence after radical prostatectomy. J Urol 1990;144:921–6.
12. Abi-Aad A.S., Macfarlane M.T., Stein A., DeKernion J.B. Detection of local recurrence after radical prostatectomy by prostate specific antigen and transrectal ultrasound. J Urol 1992;147:952–5.
13. Connolly J.A., Shinohara K., Presti J.C. Jr., Carroll P.R. Local recurrence after radical prostatectomy. characteristics in size, location, and relationship to prostatespecific antigen and surgical margins. Urology 1996;47:225–31.
14. Crook J., Robertson S., Collin G. et al. Clinical relevance of trans-rectal ultrasound, biopsy, and serum prostate-specific antigen following external beam radiotherapy for carcinoma of the prostate. Int J Radiat Oncol Biol Phys 1993;27:31–7.
15. Scattoni V., Montorsi F., Picchio M. et al. Diagnosis of local recurrence after radical prostatectomy. B J U International 2004; 93:680–8.
16. Kahn D., Williams R.D., Manyak M.J. et al. 111Indium capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer afterradical prostatectomy. The ProstScint Study Group. J Urol 1998;159(6):2041–6.
17. Raj G.V., Partin A.W., Polascik T.J. Clinical utility of Indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy. Cancer 2002;94(4):987–96.
18. Shekarriz B., Upadhyay J., Wood D.P. Jr. et al. Vesicourethral anastomosis biopsy after radical prostatectomy. Predictive value of prostate-specific antigen and pathologic stage. Urology 1999;54:1044–8.
19. Scattoni V., Roscigno M., Raber M. et al. Multiple vesico-urethral biopsies following a radical prostatectomy. The predictive roles of TRUS, DRE, PSA and the pathological stage. Eur Urol 2003; 44:407–14.
20. Saleem M.D., Sanders H., Abu El Naser M., El-Galley R. Factors predicting cancer detection in biopsy of the prostatic fossa after radical prostatectomy. Urology 1998;51:283–6.
21. Jhaveri F., Klein E. How to explore the patients with a rising PSA after radical prostatectomy: defining local versus systemic failure. Semin Urol Oncol 1999;17:130–4.
22. Moul J.W. Prostate specific antigen only progression of prostate cancer. J Urol 2000;163:1632–42.
23. Neulander E.Z., Soloway M.S. Failure after radical prostatectomy. Urology 2003;61:30–6.
24. Partin A.W., Pearson J.D., Landis P.K. et al. Evaluation of prostate specific antigen velocity after radical prostatectomy to distinguish local recurrence versus distant metastases. Urology 1994;43:649–59.
25. Patel A., Dorey F., Franklin J., DeKernion J.B. Recurrence pattern after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. J Urol 1997; 158:1441–5.
Рецензия
Для цитирования:
Демешко П.Д., Карман А.В., Суконко О.Г., Красный С.А. ФАКТОРЫ ПРОГНОЗА ПОЛОЖИТЕЛЬНЫХ РЕЗУЛЬТАТОВ МУЛЬТИФОКАЛЬНОЙ БИОПСИИ ЗОНЫ ВЕЗИКОУРЕТРАЛЬНОГО АНАСТОМОЗА У БОЛЬНЫХ С БИОХИМИЧЕСКИМ РЕЦИДИВОМ ПОСЛЕ РАДИКАЛЬНОЙ ПРОСТАТЭКТОМИИ ПО ПОВОДУ РАКА ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ. Онкоурология. 2011;7(4):59-66. https://doi.org/10.17650/1726-9776-2011-7-4-59-66
For citation:
Demeshko P.D., Karman A.V., Sukonko O.G., Krasny S.A. PROGNOSTIC FACTORS OF POSITIVE RESULTS OF MULTIFOCAL TRUS-GUIDED VESICOURETHRAL ANASTOMOSIS BIOPSY IN PATIENTS WITH BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY. Cancer Urology. 2011;7(4):59-66. (In Russ.) https://doi.org/10.17650/1726-9776-2011-7-4-59-66
Просмотров: 727
Послать статью по эл. почте 
